Drug Induced Cholestasis Index (DICI)

Drug-induced cholestasis is currently poorly detected during the preclinical stages of drug evaluation. This leads to significant drug candidate attrition during clinical drug development as well as to patient morbidity and mortality. Disturbances in bile acid (BA) homeostasis and consequent hepatic BA accumulation are postulated to be the prime mechanism of drug-induced cholestasis. 

This implies that there is an unmet need for a biorelevant in vitro model that can detect drug candidates with clinical cholestasis liability. Therefore, KaLy-Cell developed in collaboration with Katholic University of Leuven an in vitro assessment with known compounds in human and rat plateable CryoHeps (Chatterjee et al., 2014, Oorts et al., 2016).

 

For more information

Contact us

Register for our
HepatAlert notifications
for fresh or cryoplateable hepatocytes.

Request a quote!

Contact us

We look forward to
helping you find the best
solution for your
compound development
program.